Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200-Day Moving Average – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,461.88 and traded as high as GBX 1,541. Hikma Pharmaceuticals shares last traded at GBX 1,531, with a volume of 28,126,924 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIK. Jefferies Financial Group boosted their target price on Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Berenberg Bank increased their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Citigroup lifted their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

The stock’s 50-day simple moving average is GBX 1,599.21 and its 200 day simple moving average is GBX 1,461.88. The company has a market capitalization of £3.17 billion, a PE ratio of 8.70, a P/E/G ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. Insiders own 22.26% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.